FOLH1 and prostate carcinoma: The FDA's approval of [68Ga]Ga-DOTATATE positron emission tomography (PET)/CT and [177Lu]Lu-DOTATATE in 2016 and 2018 for the diagnosis and treatment of NETs, respectively, and the approval of [68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617 in 2022 for the diagnosis and treatment of prostate cancer, respectively, marked a turning point in the perception of nuclear medicine in the wider community.